Immunovia Provides an Update on its Lung Cancer Pipeline Projects

Booking.com

LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today announced that progress has been steady and continuous with its lung cancer projects.  As previously announced, Immunovia completed a test study in 2018 in collaboration with a global pharmaceutical partner. In this small study, Immunovia ́s IMMray™ could differentiate healthy controls from non-small cell lung cancer (NSCLC) with an 95% accuracy (link to PR (https://immunovia.com/media/press-releases/?id=3697)). The results demonstrated that IMMray™ has the potential to become a benchmark platform for early diagnosis of cancer diseases

Source: Immunovia Provides an Update on its Lung Cancer Pipeline Projects

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.